The abbreviations are: HDACI, histone deacetylase inhibitor; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; PDGFR, platelet derived growth factor receptor; FLT3, fms-like tyrosine kinase 3.
Introduction
The class III receptor tyrosine kinases (RTKs), including fms-like tyrosine kinase 3 (FLT3), c-KIT, and platelet-derived growth factor receptor (PDGFR) are implicated in the pathophysiology of several cancers as well as leukemias. These RTKs all share the same topology, consisting of five extracellular immunoglobulin-like domains, a juxtamembrane (JM) domain, a kinase domain interrupted by a kinase insertion domain, and an intracellular C-terminal domain [1] . Ligand binding to RTKs results in the activation of downstream effectors, including protein kinase B/Akt, signal transducers and activators of transcription (STATs) and extracellular signal-regulated kinases (ERKs) 1/2, leading to cell proliferation, differentiation and/or survival [2, 3] . Recent studies have revealed that activating mutations of RTKs frequently occur in acute myelogenous leukemia (AML) patients. For example, internal tandem duplications (ITDs) of the JM domain of FLT3 (FLT3-ITD) are present in 20-30% of de novo AML cases [4] ; and approximately 7% of AML patients possess the D835 mutation, a point mutation in the activation loop of the second kinase domain of FLT3 [4] . These mutations result in constitutively activated FLT3 and its downstream signal pathways, and are associated with elevated blast counts, increased relapse rates and poor overall survival in AML [5] [6] [7] [8] . Mutations of c-KIT and PDGFR are also associated with subsets Nishioka, et al. 5 of AML [9] [10] [11] [12] . Therefore, RTK is a therapeutic target and inhibition of activity of RTK may provide a new approach in the treatment of AML patients carrying these mutations.
Heat shock protein 90 (HSP90) is a member of the HSP family and consist of α and β subunits [13] . HSP90 is ubiquitous and functions as chaperone in cytosol, where they stabilize select proteins including hormone receptors, cyclin dependent kinase 4, as well as, RTKs [14] . In addition, HSP90 chaperone complexes prevent degradation of mutated proteins including FLT3-ITD, sustaining the function of these proteins [14] .
Recent studies showed that inhibition of HSP90 by 17-allylamino-demethoxy geldanamycin (17-AAG) provoked degradation of FLT3-ITD via ubiquitin/proteasome pathway and inhibited the proliferation of leukemia cells with FLT3-ITD [15, 16] .
Deacetylation of HSP90 at K294 mediated by HDAC6 is critical for chaperon function; when HDAC6 was genetically knocked down, HSP90 k294 was acetylated and ATP binding to HSP90 was blocked, resulted in impairment of its chaperon function [17] . The hydroxamic acid analogue pan-HDACIs, LAQ824 and LBH589 preferentially inhibit HDAC6 [18] . Both induced acetylation and inhibition of HSP90, resulting in degradation of BCR/ABL oncoprotein and Akt in chronic myeloid leukemia K562 cells [18] .
MS-275, a novel and orally available synthetic benzamide HDACI, perferentially Nishioka, et al. 6 inhibits HDAC1, and does not possess activity against HDAC6 [19, 20] . The in vitro enzymatic assay showed that IC50 of MS-275 against HDAC1 was 2.2 μM. On the other hand, even 100 μM of MS-275 was not able to inhibit the enzymatic activity of HDAC6 [21] . MS-275 induced differentiation and/or apoptosis of human leukemia U937, HL-60, K562 and Jurkat cells [21, 22] . This study examined the effects of MS-275 on human leukemia cells expressing FLT3-ITD. Also, we investigated the drug interaction of MS-275 and the novel MEK/ERK inhibitor AZD6244 (ARRY-142886) [23] with these cells.
Materials and Methods
Cells. Characteristics of the cell lines utilized in this study have been described [24] .
Leukemia cells from patients were freshly isolated with informed consent and institutional review board approval. The informed consent was provided according to the Declaration of Helsinki. 
Reagents. MS-275 was provided by

Growth inhibition assays.
To assess the anti-proliferative effect of MS-275 against various types of leukemia cells, either 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay or 3 H-thymidine uptake was utilized for leukemia cell lines or freshly isolated leukemia cells from patients, respectively, as previously described [24] . All experiments were performed in triplicate and repeated at least three times.
FLT3 genotyping. FLT3-ITD mutation was examined as previously described [24] .
Cell cycle analysis by flow cytometry. Cell cycle analysis was performed as previously described [24] .
Apoptosis assays. The ability of MS-275 to induce apoptosis of leukemia cells was measured using the annexin V-FITC apoptosis detection kit (Pharmingen, Inc., San Diego, CA), according to the manufacturer's instructions. antibody and protein G Sepharose (Pierce, Rockford, IL), as previously described [23] .
The precipitated samples were subjected to Western blot analysis, as previously described [24] . The membrane was sequentially probed with the indicated antibodies.
Western blot analysis. Western blot analysis was done as described previously [24] .
Anti-Bcl-2 (Santa Cruz), -Bcl-xL (Cell signaling), -Mcl-1 (Santa Cruz), and -α-tubulin (Santa Cruz) antibodies were used.
Data analysis. The combination index (CI) for growth inhibition elicited by MS-275
and AZD6244 in leukemia cells was calculated using the median effect method of Chou and Talalay [25] (Calcusyn Software available from Biosoft, Cambridge, United Kingdom). CI values <1 indicate synergy, a CI = 1 indicates an additive effect, and a CI >1 indicates antagonism between the two agents.
Statistical analysis. Statistical analyses were carried out using the SPSS software (SPSS Japan, Tokyo, Japan) and the results were considered to be significant when the P-value was < 0.05, and highly significant, when the P-value was < 0.01. To assess the difference between two groups under multiple conditions, one-way ANOVA followed by Boneferroni's multiple comparison tests were performed by using PRISM statistical analysis software (GraphPad Software Inc, San Diego, CA, USA). (Table 1) . Moreover, MS-275 was able to inhibit the proliferation of freshly-isolated leukemia cells with FLT3-ITD ( Table 2) . (Fig. 1B) .
Results
MS
Effect of MS-
MS-275 decreases levels of Bcl-2 family members in leukemia cells.
Bcl-xL plays a pivotal role in FLT3 kinase inhibitor-mediated apoptosis in FLT3-ITD expressing leukemia cells [26] . Exposure of MOLM13 and MV4-11 cells to MS-275 (0.5 or 1μM, 48 hrs) lowered levels of Bcl-xL and Mcl-1, while levels of Bcl-2 did not change (Fig.1C) . As levels of anti-apoptotic protein decreased, caspases 3 and 9 were activated, as indicated by the appearance of the cleaved forms of these proteins, leading to cleavage of PARP, a feature characteristic of apoptosis (Fig.1C) . 3B ). We further confirmed MS-275-induced acetylation of HSP90 in MV4-11 and MOLM13 cells by immunoprecipitation followed by Western blot analysis (Fig. 3C ). In parallel with this, direct interaction between HSP90 and FLT3 was inhibited, resulting in ubiquitination of FLT3 in these cells (Fig 3D) . Polyubiquitination of client proteins results in degradation by 26 S proteasome [28, 29] . Pretreatment of MV4-11 and freshly-isolated leukemia cells (#1 and #2 in Table 2 ) with the proteasome inhibitor PS-341 (1 nM, 1 hr) blunted MS-275-induced downregulation of FLT3 (Fig. 3E) , confirming that the FLT3 protein was degraded via ubiquitin/proteasome pathway. When these cells were exposed to a combination of both of these compounds, p-ERK positive population decreased to 2 % in both cell lines (Fig. 4A) . We next examined the effect of the combination of MS-275 and AZD6244 on proliferation of MV4-11 and 
MS-275 inhibits FLT3 and its downstream signal pathways in MOLM13 and
Discussion
This study found that MS-275, a novel HDACI with selectivity against HDAC1, induced growth arrest and apoptosis of FLT3-ITD expressing MV4-11 and MOLM13 leukemia cells (Fig 1, Table 1 ). MS-275 induced acetylation of HSP90 and ubiquitination of FLT3, which provoked degradation of FLT3 via the proteasome pathway (Fig 3) . Previous studies showed that HDAC6 deacetylased HSP90, stabilized chaperone complexes, and prevented client proteins from proteasome-mediated degradation. This study suggested that HDAC1 was also involved in deacetylation and stabilization of chaperone proteins. 
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